RECRUITING

Lovenox With Aspirin in Thawed Blastocyst Transfer

Talk to us

Conditions

Infertility, Female

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This prospective randomized trial will compare outcomes in patients receiving aspirin in combination with a low-molecular weight heparin and those under this center's standard protocol receiving neither medication, in order to determine if these medications may improve success rates.

Official Title

Lovenox With Aspirin in Thawed Blastocyst Transfer

Quick Facts

Study Start:2024-01-26
Study Completion:2024-12-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06133803

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 42 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Female patient 18-42 years of age with frozen embryos or oocytes seeking embryo transfer.
  2. 2. Use of pre-implantation genetically tested (PGT) blastocysts is allowed but not required.
  3. 3. Use of donated embryos or embryos derived from donated eggs is allowed.
  4. 4. Prior history of successful, failed, and/or canceled IVF cycles are allowed.
  1. 1. Minor (age\<18 years).
  2. 2. Currently pregnant.
  3. 3. Unable to provide informed consent in English.
  4. 4. Gestational carrier or "surrogate".
  5. 5. Blastocysts frozen at another center (Oocytes frozen elsewhere is acceptable).
  6. 6. Subject intending or having "natural cycle" thaw transfer with an active ovarian follicle present.
  7. 7. Currently participating in any other research study.
  8. 8. Subject already had an embryo transfer under this study.
  9. 9. History of thrombocytopenia (reduced platelets), bleeding disorders, or routinely using anti-coagulant medication.
  10. 10. Hypersensitivity to aspirin, heparin, or benzyl alcohol.
  11. 11. Anyone for whom the physician assesses this protocol is inappropriate or unsafe.

Contacts and Locations

Study Contact

Shironda Anderson
CONTACT
702-254-1777
shironda@fertilitycenterlv.com

Principal Investigator

Bruce Shapiro, MD, PhD
PRINCIPAL_INVESTIGATOR
Fertility Center of Las Vegas

Study Locations (Sites)

Fertility center of Las Vegas
Las Vegas, Nevada, 89117
United States

Collaborators and Investigators

Sponsor: Fertility Center of Las Vegas

  • Bruce Shapiro, MD, PhD, PRINCIPAL_INVESTIGATOR, Fertility Center of Las Vegas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-26
Study Completion Date2024-12-15

Study Record Updates

Study Start Date2024-01-26
Study Completion Date2024-12-15

Terms related to this study

Additional Relevant MeSH Terms

  • Infertility, Female